Cailin Conner

DocwireNews

A prospective study of 260 patients with gout found that the risk of gout flares induced by initiating urate-lowering therapy (ULT) was associated with higher baseline serum urate levels as well as greater decrease in serum urate during ULT. The research was published in the <a href="https://www.dovepress.com/the-effect-of-decrease-in-serum-urate-for-the-risk-of-gout-flares-duri-peer-reviewed-fulltext-article-JIR" target="_blank" rel="noopener">Journal of Inflammation Research</a>.
“Higher baseline serum urate or higher initial urate-lowering medication dose increased risk of gout flares during ULT initiation. The decrease in serum urate may play a crucial role in this process,” the investigators wrote. “Therefore, we aim to explore the relationship between decrease in serum urate and the risk of gout flares during ULT initiation.”
Investigators followed a cohort of male gout patients over a 12-week period. Participants were grouped based on their baseline serum urate levels: 7-7.9 mg/dL, 8-8.9 mg/dL, and ≥9 mg/dL. All patients received febuxostat, starting at 20 mg daily during weeks 0-4 and then escalating to 40 mg daily during weeks 4-12 if their serum urate remained above 6 mg/dL. The main outcomes of the study were the number of gout flares and the reduction in serum urate levels.
The study found that 44.2% of all participants experienced at least 1 gout flare during the 12-week observation period.
Following multivariate Poisson regression, the investigators found that the decrease in serum urate levels over the zero- to 12-week period was significantly associated with an increased risk of gout flares (incident rate ratio [IRR], 1.184; 95% CI, 1.062-1.320; P=.002). This indicates that a greater reduction in serum urate during the early weeks of ULT was linked to a higher likelihood of gout flares. Other factors independently associated with gout flares included the number of gout flares experienced in the year prior to treatment initiation and the presence of tophi.
However, following a second regression analysis, when baseline serum urate levels were included as a variable, the association between the decrease in serum urate levels and gout flares was no longer statistically significant (IRR, 1.055; 95% CI, 0.923-1.207; P=.433). Instead, the baseline serum urate level and the number of gout flares experienced in the year before treatment remained independently associated with gout flares.
For patients with gout, the authors recommended that “they follow the prescribed ULT regimen, monitor their serum urate levels regularly, and carry anti-inflammatory prophylaxis medication in pocket when starting ULT.”

Laura Litwin

Do Disparities in Minimally-Invasive Surgery Access Influence Mortality in Early-Stage NSCLC?

Non-Small Cell Lung Cancer

Dr. Dimitry Sayenko

Treatments for Paralysis and Neurologic Loss

Neurology

Cecilia Brown

Is the COVID-19 Vaccine Effective for Patients With Lung Cancer?

Lung Cancer

Latest News

Risk of Gout Flares After ULT Initiation Depends on Degree of Serum Urate Decrease

Gout

During urate-lowering therapy initiation, the risk of gout flares is influenced by both higher baseline serum urate levels and a greater decrease in serum urate.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe